• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.78 EUR-0.20 %10/7 9:20
5,653 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.20 %
+7.47 %
+8.31 %
-27.82 %
-31.13 %
-33.24 %
+173.95 %
+144.50 %
-98.39 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
78.97M EUR
Turnover
3.05K EUR
P/E (adj.) (26e)
78.3
EV/EBIT (adj.) (26e)
63.55
P/B (26e)
7.73
EV/S (26e)
6.04
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
2026-05-14
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-05-15

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications Press Release, Helsinki, 10 July 2026 at 9 AM (EEST) Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications Nexstim Plc (“Nexstim” or the “Company”) ...
1 hour ago
by Kyhnykeisari
29
That’s exactly what’s so tempting! There’s plenty of room for growth!
7/8/2026, 6:49 AM
by Optimistinen verkkapöksy
18
Sinaptica is firing up its first machine this July in Florida, so the research continues, and we’re hoping for some strong results.
11 hours ago
15
Sinaptica CEO as a guest
17 hours ago
by Kyhnykeisari
13
A great place for an order: Malaysia is a highly developed technology nation, and it is one of the leading digital economies in Southeast Asia, right after Singapore. The country ranks high in the global competitiveness index at 15th place and has taken significant leaps, particularly...
7/8/2026, 6:31 AM
by Lovaskarhu
11
Well, tell us, is there any profitable growth company that would be better than this one? This year will also be profitable, and profit is conservatively estimated to be +20-40% compared to last year. In my books, there is nothing better than this.
yesterday
by Informaatio
4
Positive news won’t drive the stock price up until there’s concrete information on the growth percentage at which this story is advancing. Nothing to do but wait for the H1 report on August 14th, unless bigger news comes out before then. Still, the story is progressing consistently...
24 minutes ago
by Optimistinen verkkapöksy
3
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

Press release2026-07-10 08:00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release2026-07-08 08:00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release2026-07-07 08:00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
New NBS 6 system order for Nexstim from USA
Analyst Comment2026-07-06 08:17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release2026-07-03 08:00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment2026-06-12 08:28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release2026-06-11 08:00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment2026-06-04 07:48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release2026-06-03 09:00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release2026-05-25 08:00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release2026-05-18 16:00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release2026-05-15 13:40

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release2026-05-15 13:40

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release2026-05-15 13:40

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release2026-05-15 13:40

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Nexstim strengthens its balance sheet
Research2026-05-15 08:00 by
Antti Siltanen

Nexstim strengthens its balance sheet

The 5 MEUR financing supports the growth strategy.

Nexstim
Regulatory press release2026-05-13 16:00

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim
Regulatory press release2026-05-13 16:00

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release2026-05-13 16:00

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release2026-05-13 16:00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim